Az lf-csatorna gátlásától a stabil anginás beteg kezeléséig Az ivabradin

Translated title of the contribution: Ivabradine - From If inhibition to the treatment of patients with stable angina

Kolozsvári Rudolf, I. Édes

Research output: Contribution to journalArticle

Abstract

Ivabradine is a new agent that selectively inhibits the I, channels of the sinus node. Electro-physiological studies have shown a significant heart rate lowering effect of ivabradine compared to placebo, while no significant changes have been observed in the frequency-corrected QT interval (QTc) or in the conductivity or refractoriness of the atrial muscle, AV node, His-Purkinje system or ventricular muscle. In a noninferiority study that compared ivabradine to atenolol, the same efficacy was shown in terms of increasing effort tolerance and reducing anginal events, with less reduction in heart rate. The same results were obtained with the comparison to amlodipine - the two drugs were equally efficient. The longest trial investigated the efficacy and safety of ivabradine for 12 month; both heart rate and the number of anginal episodes significantly decreased during the entire study period. The ongoing BEAUTIFUL trial tests ivabradine in patients with heart failure. The only important side effect of ivabradine is phosphenes, but this rarely requires the treatment to be discontinued. No other side effects such as symptomatic bradycardia or conduction abnormalities have been observed. Ivabradine is currently indicated as an alternative treatment of stable angina pectoris.

Original languageHungarian
Pages (from-to)41-45
Number of pages5
JournalLege Artis Medicinae
Volume17
Issue numberSUPPL. 2
Publication statusPublished - 2007

Fingerprint

ivabradine
Stable Angina
Heart Rate
Therapeutics
Phosphenes
Amlodipine
Muscles
Atrioventricular Node
Sinoatrial Node
Atenolol
Bradycardia
Inhibition (Psychology)
Heart Failure
Placebos

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Az lf-csatorna gátlásától a stabil anginás beteg kezeléséig Az ivabradin. / Rudolf, Kolozsvári; Édes, I.

In: Lege Artis Medicinae, Vol. 17, No. SUPPL. 2, 2007, p. 41-45.

Research output: Contribution to journalArticle

@article{8a55ca0a9c0149c08cc7fda87f7f9992,
title = "Az lf-csatorna g{\'a}tl{\'a}s{\'a}t{\'o}l a stabil angin{\'a}s beteg kezel{\'e}s{\'e}ig Az ivabradin",
abstract = "Ivabradine is a new agent that selectively inhibits the I, channels of the sinus node. Electro-physiological studies have shown a significant heart rate lowering effect of ivabradine compared to placebo, while no significant changes have been observed in the frequency-corrected QT interval (QTc) or in the conductivity or refractoriness of the atrial muscle, AV node, His-Purkinje system or ventricular muscle. In a noninferiority study that compared ivabradine to atenolol, the same efficacy was shown in terms of increasing effort tolerance and reducing anginal events, with less reduction in heart rate. The same results were obtained with the comparison to amlodipine - the two drugs were equally efficient. The longest trial investigated the efficacy and safety of ivabradine for 12 month; both heart rate and the number of anginal episodes significantly decreased during the entire study period. The ongoing BEAUTIFUL trial tests ivabradine in patients with heart failure. The only important side effect of ivabradine is phosphenes, but this rarely requires the treatment to be discontinued. No other side effects such as symptomatic bradycardia or conduction abnormalities have been observed. Ivabradine is currently indicated as an alternative treatment of stable angina pectoris.",
keywords = "Effort tolerance, Heart rate, Ivabradine",
author = "Kolozsv{\'a}ri Rudolf and I. {\'E}des",
year = "2007",
language = "Hungarian",
volume = "17",
pages = "41--45",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "SUPPL. 2",

}

TY - JOUR

T1 - Az lf-csatorna gátlásától a stabil anginás beteg kezeléséig Az ivabradin

AU - Rudolf, Kolozsvári

AU - Édes, I.

PY - 2007

Y1 - 2007

N2 - Ivabradine is a new agent that selectively inhibits the I, channels of the sinus node. Electro-physiological studies have shown a significant heart rate lowering effect of ivabradine compared to placebo, while no significant changes have been observed in the frequency-corrected QT interval (QTc) or in the conductivity or refractoriness of the atrial muscle, AV node, His-Purkinje system or ventricular muscle. In a noninferiority study that compared ivabradine to atenolol, the same efficacy was shown in terms of increasing effort tolerance and reducing anginal events, with less reduction in heart rate. The same results were obtained with the comparison to amlodipine - the two drugs were equally efficient. The longest trial investigated the efficacy and safety of ivabradine for 12 month; both heart rate and the number of anginal episodes significantly decreased during the entire study period. The ongoing BEAUTIFUL trial tests ivabradine in patients with heart failure. The only important side effect of ivabradine is phosphenes, but this rarely requires the treatment to be discontinued. No other side effects such as symptomatic bradycardia or conduction abnormalities have been observed. Ivabradine is currently indicated as an alternative treatment of stable angina pectoris.

AB - Ivabradine is a new agent that selectively inhibits the I, channels of the sinus node. Electro-physiological studies have shown a significant heart rate lowering effect of ivabradine compared to placebo, while no significant changes have been observed in the frequency-corrected QT interval (QTc) or in the conductivity or refractoriness of the atrial muscle, AV node, His-Purkinje system or ventricular muscle. In a noninferiority study that compared ivabradine to atenolol, the same efficacy was shown in terms of increasing effort tolerance and reducing anginal events, with less reduction in heart rate. The same results were obtained with the comparison to amlodipine - the two drugs were equally efficient. The longest trial investigated the efficacy and safety of ivabradine for 12 month; both heart rate and the number of anginal episodes significantly decreased during the entire study period. The ongoing BEAUTIFUL trial tests ivabradine in patients with heart failure. The only important side effect of ivabradine is phosphenes, but this rarely requires the treatment to be discontinued. No other side effects such as symptomatic bradycardia or conduction abnormalities have been observed. Ivabradine is currently indicated as an alternative treatment of stable angina pectoris.

KW - Effort tolerance

KW - Heart rate

KW - Ivabradine

UR - http://www.scopus.com/inward/record.url?scp=34249879303&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249879303&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 41

EP - 45

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - SUPPL. 2

ER -